Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 156 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MYjDfZRwfG:6aXOgRZN{[Xl? NFHOOFA2OCEQvF2= NIC2U5M1QCCq NYHBWJAyTE2VTx?= MYrLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml M1iyOVExPDl7NkSz
OVCA 429 MVHGeY5kfGmxbjDBd5NigQ>? NUjCSHRUOzByIH7N M4n5WFQ5KGh? MW\EUXNQ M1u3V2Rqe3K3cITzJIlvfGGldDDteYx1cWOnbHz1cIFzKHS3bX;yJJNxcGW{b3nkdy=> NIL1[4oyODl7OUe2Oi=>
RPMI8226 NHn1eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzVWHYyODBibl2= M3PiO|Q5KGh? NEm1VYZFVVOR M2Xq[WlEPTB;M{Cgcm0> MmjHNVE{ODZ2OEm=
Dox40 M1Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\4NXBDOTByIH7N Mnv4OFghcA>? MkfsSG1UVw>? NWqyVItRUUN3ME20NEBvVQ>? M3XH[VEyOzB4NEi5
MR20 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3xSlJNOTByIH7N MkPhOFghcA>? M4fLd2ROW09? NH7iZYVKSzVyPUKwJI5O NUjObJR1OTF|ME[0PFk>
LR5 NYf3PVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi4NVAxKG6P NYnGZnU3PDhiaB?= MmjSSG1UVw>? MnfxTWM2OD1{MDDuUS=> M1TTR|EyOzB4NEi5
U266 NYLvTWtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XjfVExOCCwTR?= Mn3ZOFghcA>? M1PEOWROW09? MnfYTWM2OD1|IH7N MYOxNVMxPjR6OR?=
IM-9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3THdFExOCCwTR?= NV;qSoR6PDhiaB?= NVXnPYQ4TE2VTx?= MXfJR|UxRTZibl2= MVuxNVMxPjR6OR?=
Hs Sultan MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnMWm8yODBibl2= NHXzSWY1QCCq MkLESG1UVw>? NX7TUo9CUUN3ME2yNEBvVQ>? Mo\TNVE{ODZ2OEm=
PAM-LY2 NH3iTmtHfW6ldHnvckBCe3OjeR?= MmP2NVAxKG6P MnPuNVIhcA>? M{L6NGROW09? MXvJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= NX7sNmZiOTF|NUC5NVM>
PAM 212 NHnUTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L5Z|ExOCCwTR?= MVG3NkBp M1HVPGROW09? MoDETY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MX:xNVM2ODlzMx?=
PAM-LY2 M3nKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxNFAhdk1? MoqyO|IhcA>? NHzhelhFVVOR MmPWTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M4LhVlEyOzVyOUGz
B4B8 NGDVWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXz[JJwOTByIH7N MX63NkBp MUDEUXNQ NH;u[nFKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MVOxNVM2ODlzMx?=
B7E3 NXnjNZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X3VlExOCCwTR?= M1\5blczKGh? MVLEUXNQ MmX4TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M1PYOFEyOzVyOUGz
UM-SCC-9 M2e1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T4S|ExOCCwTR?= NH;xVoM4OiCq NXTnfWg3TE2VTx?= NWftWIxSUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M2f4d|EyOzVyOUGz
UM-SCC-11B NVrlS5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ibFExOCCwTR?= MkfqO|IhcA>? M{X1cmROW09? MlXkTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M{DPNFEyOzVyOUGz
H460 NY\pdnUzTnWwY4Tpc44hSXO|YYm= NUjaNpJIOTBizszN NETZVpczPCCq Mlq4SG1UVw>? NXHkfZo{UW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?= MnPBNVI1QTJzMUe=
U266 NXj4Z4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:1NFAhdmdxbXy= NYG1[XVpPDhiaB?= NIPISWNFVVOR NHG4SHBKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NXzsWYIzOTJ4M{G2NVk>
ARH77 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDzPXZMPTByIH7nM41t MWC0PEBp MYHEUXNQ NHLNc4pKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MXSxNlY{OTZzOR?=
WAD-1 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy1NFAhdmdxbXy= MnzvOFghcA>? MVzEUXNQ MnXxTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4TGfVEzPjNzNkG5
U266/LR7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTEOVAxKG6pL33s MoCxOFghcA>? NYHYPVBlTE2VTx?= MX;Jcohq[mm2czDj[YxtKGe{b4f0bC=> MY[xNlY{OTZzOR?=
U266/dox4 NFnNVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELjT202ODBibnevcYw> M4Xo[|Q5KGh? NVv0eJFFTE2VTx?= MmPDTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NGL5NGoyOjZ|MU[xPS=>
RPMI8226/LR5 NGjtNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO1NFAhdmdxbXy= M1juOFQ5KGh? NIfXN4NFVVOR NIPsfJJKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NGe2c5YyOjZ|MU[xPS=>
H460 M3TQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPCSGoyOCEQvF2= NF\zOYc4OiCq Mlv3SG1UVw>? NWjpZndbUUN3ME2xNFAhdk1? M4TxcFEzPjNzNkKw
H358 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmyeJF[OTBizszN MYO3NkBp MlX1SG1UVw>? M3jJbWlEPTB;N{Cgcm0> NVvMPJM2OTJ4M{G2NlA>
H322 M4XQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPv[3NWOTBizszN NEXMdo84OiCq NWjVUIZuTE2VTx?= MV\JR|UxRTZ{MDDuUS=> MVGxNlY{OTZ{MB?=
H460 NX7NXIx3TnWwY4Tpc44hSXO|YYm= MVyxNFAhdk1? NF[0dXAzPCCq MUfEUXNQ NEDreZJKdmS3Y3XzJGczNU1vcHjhd4Uh[XK{ZYP0JIFv\CC2dXL1cIlvKGG|c3XtZox6NWSrc3Hzd4Vu[my7 MXixNlY{OTZ{MB?=
LNCap-Pro5 NEfZRpdHfW6ldHnvckBCe3OjeR?= NIPOTm4yKM7:TR?= MUC0JIg> M1nVWWROW09? NHK3[2hUfGGkaXzpfoV{KHB3Mx?= NVG1fZdCOTR4MUK1N|I>
T29 MYTBdI9xfG:|aYOgRZN{[Xl? M17Td|UxKG6P MUW0PEBpKA>? NXfiZodETE2VTx?= M3;IPWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXq1NZRVOTZ5N{ixO|k>
T29Kt1 M131fGFxd3C2b4Ppd{BCe3OjeR?= M{PnZVUxKG6P NXryN|h7PDhiaDC= M4XFfGROW09? MWfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NGPn[|QyPjd5OEG3PS=>
HCT116 M{jyRmFxd3C2b4Ppd{BCe3OjeR?= MmLvOVAhdk1? NUW4dYtIPDhiaDC= M1PRfmROW09? Mkj2TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWHWfXAxOTZ5N{ixO|k>
HKe-3 NXPQWpJQSXCxcITvd4l{KEG|c3H5 MVy1NEBvVQ>? MmDGOFghcCB? M2LHfmROW09? M3rpVmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlTaNVY4PzhzN{m=
NB-1691 M4\Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDVbnBsOSEQvF2= NUHUXnpxPzJiaB?= M{ezcmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NIPwO5gyPzZ6OU[4OC=>
CHLA-255 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fhRVEh|ryP MniwO|IhcA>? NFPyN|lKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= M4fO[|E4Pjh7Nki0
SK-N-AS NIXLcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxJO69VQ>? MmPqO|IhcA>? NUDGdIFLUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> Ml35NVc3QDl4OES=
NB-1691 M3zFXWZ2dmO2aX;uJGF{e2G7 Mmf1NVAhdk1? NGfKO5EzPCCq MX\TbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl M171dVE4Pjh7Nki0
CHLA-255 MnH2SpVv[3Srb36gRZN{[Xl? M2nGRlExKG6P M4\4XFI1KGh? MX3Nc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? MVmxO|Y5QTZ6NB?=
RPMI 8226 MkLQSpVv[3Srb36gRZN{[Xl? NYjy[XRLOjBibl2= MVy4JIg> M2jZOHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M2XobVE6PDN4MEWw
MM.1S M1fBfmZ2dmO2aX;uJGF{e2G7 NGP1RWczOCCwTR?= NF\Oepo5KGh? MVvTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M4PxO|E6PDN4MEWw
U266 MmTRSpVv[3Srb36gRZN{[Xl? NVHkdoVlOjBibl2= MmXRPEBp Ml\XV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MmrFNVk1OzZyNUC=
OPM1 MlPvSpVv[3Srb36gRZN{[Xl? M3z2ZlIxKG6P NGq1Upk5KGh? MV7TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NHX2S48yQTR|NkC1NC=>
INA6 NXrzWHBJTnWwY4Tpc44hSXO|YYm= MVWyNEBvVQ>? NH;2Xpc5KGh? NH;BdW5UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NXTlVYlzOTl2M{[wOVA>
OPM2 NWjDfGN{TnWwY4Tpc44hSXO|YYm= MVKyNEBvVQ>? M3XENlghcA>? MVrTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MWCxPVQ{PjB3MB?=
RPMI 8226 M1;SU2Z2dmO2aX;uJGF{e2G7 NFuwb2EzOCCwTR?= MX:4JIg> NYfFfXAzUW6mdXPld{BFVkFic4nueIhme2m| MkjMNVk1OzZyNUC=
BaF/3 NIThXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWixNFAhdk1? M2DKXVQ5KGh? NW\oOnNxUUN3ME22MlIhdk1? M3\jRlIxOzB3Nkmy
BaF/3-p210 NX;udpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDtbYtEOTByIH7N M2\vWFQ5KGh? NI\sS29KSzVyPUSuO{BvVQ>? MnnTNlA{ODV4OUK=
TCC-S NHjO[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7LRXFMOTByIH7N M3ziS|Q5KGh? MYPJR|UxRTJwODDuUS=> MmCwNlA{ODV4OUK=
BaF/3 NILxb4FHfW6ldHnvckBCe3OjeR?= MXG2JI5O NVjiVJIxPDhiaB?= M3LkWWlv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> NH\LO2IzODNyNU[5Ni=>
BaF/3-p210 NUTkemxQTnWwY4Tpc44hSXO|YYm= MVm2JI5O NU\YXItMPDhiaB?= NXu0Wm8zUW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>? NWHtcpFjOjB|MEW2PVI>
BaF/3-p210 NIDNbYdHfW6ldHnvckBCe3OjeR?= NInubGs3KG6P NYP2eVRiOjRiaB?= MVjS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? MWSyNFMxPTZ7Mh?=
Raji MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWexJO69VQ>? NXvPZ|NHOjRiaB?= MXXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NEnS[2ozOTF5MEm4PC=>
LCL-1 NHjXcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PKPFEh|ryP M1PS[|I1KGh? NHvXXG9T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NYntRZR1OjFzN{C5PFg>
LCL-2 M4DhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXx[VYzOSEQvF2= NYLPXIg1OjRiaB?= M17JcXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXqyNVE4ODl6OB?=
BJAB NHXGfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX73bWM5OSEQvF2= NHzxblIzPCCq NHrpPGZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NFGyeXIzOTF5MEm4PC=>
SNT-13 NF3wOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;vOVEh|ryP NUfIT4pkOjRiaB?= M{nJbHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MX[yNVE4ODl6OB?=
SNT-16 M37DSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP2NUDPxE1? MlqxNlQhcA>? MWDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MVGyNVE4ODl6OB?=
Jurkat NXHDW4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF72bo0yKM7:TR?= NWPiTnJbOjRiaB?= MWLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MYiyNVE4ODl6OB?=
KAI-3 NGO4Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjK[WM2OSEQvF2= MnHRNlQhcA>? NGHiU3FT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVv1fYhKOjFzN{C5PFg>
SNK-6 M4TwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPaeoQyKM7:TR?= M3PYSFI1KGh? MXvS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M4K2RlIyOTdyOUi4
KHYG-1 NXjNOmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xJO69VQ>? NUD2VpR7OjRiaB?= NIPlbnVT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M4f6XlIyOTdyOUi4
SNT-16 NFHRTpdCeG:ydH;zbZMhSXO|YYm= M1HqeFEh|ryP M2[4bFYhcA>? NVXaXIZbUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Ml3oNlEyPzB7OEi=
Jurkat Mo\xRZBweHSxc3nzJGF{e2G7 MXyxJO69VQ>? MUW2JIg> NGnPS2dKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M37SclIyOTdyOUi4
KAI-3 NIfOVFFCeG:ydH;zbZMhSXO|YYm= M3XOWlEh|ryP NFPEXJM3KGh? MoHXTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlzlNlEyPzB7OEi=
KHYG-1 NG[5U3JCeG:ydH;zbZMhSXO|YYm= MXmxJO69VQ>? MmryOkBp NEXS[IFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3rqXVIyOTdyOUi4
SNT-13 M4fYUGFvfGm4aYLhcEBCe3OjeR?= NYXScIE1OSEQvF2= M3;DPFI1KGh? MljnTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NXLFS2FLOjFzN{C5PFg>
SNT-16 NVTFbmJ7SW62aY\pdoFtKEG|c3H5 NUPkR2UzOSEQvF2= M1XQc|I1KGh? MXrJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NY\3TYhJOjFzN{C5PFg>
KAI-3 M4\qN2FvfGm4aYLhcEBCe3OjeR?= MmO2NUDPxE1? NHXX[XgzPCCq M37hWmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? Mn3aNlEyPzB7OEi=
SNK-6 M3jUPGFvfGm4aYLhcEBCe3OjeR?= M4jDeVEh|ryP NEXyNXgzPCCq MYTJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NHKzXnYzOTF5MEm4PC=>
RAW 264.7 NYL1WXo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPF[JcyODBibl2= NUHFUoY3PDhiaB?= Mnz0VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NH;ZTpAzOjR{N{G1OC=>
A375 MVzBdI9xfG:|aYOgRZN{[Xl? M4n6OlExKG6P NFXhb2gzPCCq M3j1SWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkfVNlMxPzlyOEO=
BLM NFfqW|VCeG:ydH;zbZMhSXO|YYm= NUjuUFl4OTBibl2= M{nCU|I1KGh? M3m2cGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NF25OY8zOzB5OUC4Ny=>
A375 MXvBeZRweGijZ4mgRZN{[Xl? NFHvSXkyOCCwTR?= MX:xNkBp NHjZfo5KdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M3\Td|I{ODd7MEiz
BLM M3LNUGF2fG:yaHHnfUBCe3OjeR?= MYmxNEBvVQ>? NXTtOGdiOTJiaB?= MkPwTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MYOyN|A4QTB6Mx?=
H1299 MmPwRZBweHSxc3nzJGF{e2G7 MnnzPFAhdk1? NXLRXmJTOjRiaB?= MoPNSG1UVw>? M3;RbXNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| M3\lRVI2OzJ|Nkmz
Hut-78 MoPySpVv[3Srb36gRZN{[Xl? NVnxfWZVOTByIH7N MXqyOEBp MXjEUXNQ Mn\uSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w NFTzeFUzPTZ6MUOzOS=>
H9 M4WwOmZ2dmO2aX;uJGF{e2G7 Mkm3NVAxKG6P Mn\NNlQhcA>? MmTvSG1UVw>? M3rzWGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= MlnkNlU3QDF|M{W=
HH NG\FO25HfW6ldHnvckBCe3OjeR?= NHPmZlYyODBibl2= NYXUN4E1OjRiaB?= MYLEUXNQ NVPUSlFv\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u MV:yOVY5OTN|NR?=
Hut-78 NX;ldFZHVWmpcnH0bY9vKEG|c3H5 MVKxNFAhdk1? NVfSRm9FOjRiaB?= NYLXRZo4TE2VTx?= NUfaRXVwWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> MYKyOVY5OTN|NR?=
HH NXL1e4Y3VWmpcnH0bY9vKEG|c3H5 NGnkSFMyODBibl2= MXmyOEBp MYfEUXNQ NIqyN5VT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl NULwUIF5OjV4OEGzN|U>
U937 MnP5SpVv[3Srb36gRZN{[Xl? NWi5Z20xOTByIH7N MXG2JIg> NULSUIU4UW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?= M{\6[FI2PzlzNEe3
human PBMC MojLSpVv[3Srb36gRZN{[Xl? M2\UWVExOCCwTR?= MUiyOEBp NF3kcYRKdmS3Y3XzJGlNNThicnXs[YF{\Q>? MVqyOVc6OTR5Nx?=
ES6 NH;IW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e4OWlEPTB;MD6wNFIyKG6P MkPKV2FPT0WU
SK-UT-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMU[zJI5O MW\TRW5ITVJ?
SH-4 M3Hs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXlTWM2OD1yLkG3N{BvVQ>? MlvVV2FPT0WU
TE-9 MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nLTGlEPTB;MD6xPFIhdk1? MYfTRW5ITVJ?
A253 NUXFc5BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4UGlEPTB;MD6yNFghdk1? MoDtV2FPT0WU
no-10 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMkGgcm0> M{TOenNCVkeHUh?=
MMAC-SF Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMkG2JI5O MoCxV2FPT0WU
A101D NH3hc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMkK1JI5O NGGyfoNUSU6JRWK=
NTERA-S-cl-D1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXLTWM2OD1yLkK0N{BvVQ>? MV3TRW5ITVJ?
8-MG-BA M1jkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPmdGlTUUN3ME2wMlI2KG6P MUXTRW5ITVJ?
KNS-42 NV;QTItVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMkW4JI5O Mn;kV2FPT0WU
LXF-289 NFT6dmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMk[5JI5O MYPTRW5ITVJ?
OVCAR-4 NH7TbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jte2lEPTB;MD6yPFkhdk1? MVXTRW5ITVJ?
LOUCY NVOwNnNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITBWGhKSzVyPUCuNlk{KG6P NFuzWFZUSU6JRWK=
BB65-RCC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwM{C0JI5O NI\RUoNUSU6JRWK=
D-542MG M3Tmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwM{K5JI5O MV7TRW5ITVJ?
ONS-76 NHW1emZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vOeGlEPTB;MD6zN{BvVQ>? MWHTRW5ITVJ?
BB30-HNC M4LFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{O1JI5O MU\TRW5ITVJ?
KS-1 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LoZ2lEPTB;MD6zOEBvVQ>? Mn;wV2FPT0WU
A388 M13iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fGWGlEPTB;MD6zOVYhdk1? M3ztW3NCVkeHUh?=
ES8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy0bYljUUN3ME2wMlQhdk1? M2XBTXNCVkeHUh?=
MZ2-MEL NITodIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvFeGZKSzVyPUCuOFA4KG6P NHTLdW9USU6JRWK=
HCC2998 NXvwSnd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrBem46UUN3ME2wMlQyOiCwTR?= MXrTRW5ITVJ?
D-247MG M2C4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzq[GFKSzVyPUCuOFE{KG6P MV3TRW5ITVJ?
ACN MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljuTWM2OD1yLkSxO{BvVQ>? NHXyNllUSU6JRWK=
LB2518-MEL NVvheYROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfhXXhNUUN3ME2wMlQzPSCwTR?= NWjV[5d3W0GQR1XS
ES1 MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\pTWM2OD1yLkSzJI5O MlnsV2FPT0WU
HCE-T NF:0S3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHoUHc1UUN3ME2wMlQ{QSCwTR?= NX3ybWhpW0GQR1XS
OS-RC-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\TUmlEPTB;MD60OEBvVQ>? M3PIfHNCVkeHUh?=
MFH-ino MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHweIFKSzVyPUCuOFQ{KG6P NUnydJdUW0GQR1XS
OCUB-M MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrCZXFKSzVyPUCuOFQ4KG6P NUPQR2w{W0GQR1XS
CP66-MEL NXfqN41PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOwTWM2OD1yLkS3N{BvVQ>? NX\tSoRlW0GQR1XS
LB771-HNC Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zOcmlEPTB;MD60O|Qhdk1? M4TSdXNCVkeHUh?=
DSH1 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwNEigcm0> MkDDV2FPT0WU
HUTU-80 M4DaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorNTWM2OD1yLkWzN{BvVQ>? NXjPUodiW0GQR1XS
CESS NF;uWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LabmlEPTB;MD61N|ghdk1? NFvoeIhUSU6JRWK=
NCI-H747 MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXztRpdDUUN3ME2wMlU{QSCwTR?= NX62SVhQW0GQR1XS
HT-144 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLMTWM2OD1yLkW3OkBvVQ>? NXy0dHFwW0GQR1XS
COLO-829 M2TtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvEcI9VUUN3ME2wMlYyPCCwTR?= NVPJ[5ZNW0GQR1XS
A4-Fuk MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHJTWM2OD1yLk[yN{BvVQ>? MWXTRW5ITVJ?
GI-ME-N NHrhOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7sOpFKSzVyPUCuOlM1KG6P NVvhNHdLW0GQR1XS
LB831-BLC M4XmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2S3NKSzVyPUCuOlQyKG6P M3XlfXNCVkeHUh?=
HOP-62 NXrYZXQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfwcJlKSzVyPUCuOlQ4KG6P NFXhPYVUSU6JRWK=
BB49-HNC NVK2bm0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzxVZhKSzVyPUCuOlUzKG6P M4rZdHNCVkeHUh?=
D-336MG MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn0c4pIUUN3ME2wMlY2PyCwTR?= MVLTRW5ITVJ?
TK10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nLXGlEPTB;MD62O|khdk1? MoD4V2FPT0WU
Ramos-2G6-4C10 NIXNdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2eySWlEPTB;MD62PVMhdk1? MWLTRW5ITVJ?
LB373-MEL-D MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\hTWM2OD1yLkegcm0> MlnHV2FPT0WU
SF126 NYLiVGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLpTWM2OD1yLkewNUBvVQ>? NHLwSmFUSU6JRWK=
UACC-257 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInTWI5KSzVyPUCuO|Ehdk1? MYPTRW5ITVJ?
KINGS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nhcmlEPTB;MD63NlIhdk1? NV7tbo1pW0GQR1XS
LS-513 NFzqSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYexWpVuUUN3ME2wMlc{QSCwTR?= M3qzVHNCVkeHUh?=
GI-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XHb2lEPTB;MD63OlQhdk1? MoLjV2FPT0WU
ES7 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rVZ2lEPTB;MD63OlYhdk1? NVPlbYhLW0GQR1XS
LB2241-RCC NYK1WXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTQb3pIUUN3ME2wMlgxPCCwTR?= MYjTRW5ITVJ?
D-263MG NGXBe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\oV5cxUUN3ME2wMlgxPyCwTR?= NYjuZo9ZW0GQR1XS
SW684 NWDhSGU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHaTWM2OD1yLkiyNUBvVQ>? NXXsWZJWW0GQR1XS
ML-2 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyxTWM2OD1yLkiyNUBvVQ>? Mn\KV2FPT0WU
SK-LMS-1 NFfrUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwOEW0JI5O NYrsNGxEW0GQR1XS
TE-5 NIX3e|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwOE[1JI5O NX;HTJdCW0GQR1XS
QIMR-WIL M3jOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG0UmxKSzVyPUCuPFg6KG6P NHjlUG1USU6JRWK=
NCI-H1355 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2niPGlEPTB;MD64PVUhdk1? MV;TRW5ITVJ?
SNB75 NXrvXoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwOUGyJI5O MmHaV2FPT0WU
RXF393 NXzpe2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXaW|FKSzVyPUCuPVE1KG6P M17FPHNCVkeHUh?=
IST-MEL1 NYjEOY0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC4VWwxUUN3ME2wMlkyPyCwTR?= NY\6WZpsW0GQR1XS
SF268 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnCdlBKSzVyPUCuPVI{KG6P MofmV2FPT0WU
KALS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwOUK1JI5O M4jve3NCVkeHUh?=
HC-1 M1SxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS2TWM2OD1yLkm3OUBvVQ>? NU\Sb5R2W0GQR1XS
SW872 M{DaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr1TWM2OD1yLkm5OkBvVQ>? NIjQPGZUSU6JRWK=
PSN1 M4LTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnXdoNKSzVyPUGuNFEhdk1? MXvTRW5ITVJ?
TE-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXxTWM2OD1zLkCzJI5O MYDTRW5ITVJ?
TE-10 NFLJZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjyRVJKSzVyPUGuNFMhdk1? NITRWlNUSU6JRWK=
RKO NYfnXGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTQXmFKSzVyPUGuNFYhdk1? M2LvWHNCVkeHUh?=
LC-2-ad MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLybZQ2UUN3ME2xMlA5KG6P MYHTRW5ITVJ?
SK-MM-2 NEXX[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnmPHpHUUN3ME2xMlA6KG6P NInpR5lUSU6JRWK=
VA-ES-BJ MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\vTWM2OD1zLkC5JI5O NH7PT3FUSU6JRWK=
MZ7-mel NGfLRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW4VFJKSzVyPUGuNFkhdk1? M2PHXXNCVkeHUh?=
D-392MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljXTWM2OD1zLkGgcm0> NFjSNIZUSU6JRWK=
CCRF-CEM M3LDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTBTWM2OD1zLkGzJI5O MYrTRW5ITVJ?
EM-2 NUTiZ49UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwMU[gcm0> M1nOfXNCVkeHUh?=
HAL-01 NFTXS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnncpJEUUN3ME2xMlE5KG6P Mm\2V2FPT0WU
TE-8 NYjnVVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fE[WlEPTB;MT6xPUBvVQ>? MWTTRW5ITVJ?
NCI-H1882 NYHHSGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\2[2NYUUN3ME2xMlIhdk1? NVn5OmpmW0GQR1XS
Daudi NHHZd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTMV3FKSzVyPUGuNlIhdk1? MV;TRW5ITVJ?
BL-41 NXy1[oZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq1eGtbUUN3ME2xMlI2KG6P NVXRcW06W0GQR1XS
SR M{m3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLHTWM2OD1zLkK1JI5O M4XwdXNCVkeHUh?=
KM12 NYDBfZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LxcmlEPTB;MT6yO{BvVQ>? NELv[o1USU6JRWK=
K5 M1nHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG1TWM2OD1zLkK4JI5O M13KOHNCVkeHUh?=
A3-KAW NGjoPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hs[WlEPTB;MT6yPEBvVQ>? NXLB[FVnW0GQR1XS
CMK MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrwdmo1UUN3ME2xMlI6KG6P M3K0T3NCVkeHUh?=
Calu-6 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPMbohKSzVyPUGuNlkhdk1? M3TKdXNCVkeHUh?=
IST-SL2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXvTWM2OD1zLkOxJI5O NVPiNnIxW0GQR1XS
OPM-2 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPdmlEPTB;MT6zN{BvVQ>? MYnTRW5ITVJ?
DU-4475 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHISmlKSzVyPUGuN|Yhdk1? MV;TRW5ITVJ?
ECC12 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwM{egcm0> MWTTRW5ITVJ?
L-540 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwM{egcm0> M1fFUHNCVkeHUh?=
CAS-1 M2S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PnPWlEPTB;MT6zO{BvVQ>? NGrnTHdUSU6JRWK=
PF-382 NXTpUI1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzXUZNKSzVyPUGuOFchdk1? MnvoV2FPT0WU
LS-411N NVXadlNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTRUo5rUUN3ME2xMlU{KG6P MVzTRW5ITVJ?
NCI-H69 NYT2UHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwNUSgcm0> MnTtV2FPT0WU
NB12 NH;mU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG5S2dKSzVyPUGuOVYhdk1? NGnlZplUSU6JRWK=
HEL NGnHcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3mTWM2OD1zLk[xJI5O MlrGV2FPT0WU
GCIY Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljRTWM2OD1zLk[yJI5O NXzESZBSW0GQR1XS
EHEB NI[4WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Wyc2lEPTB;MT62O{BvVQ>? MoXyV2FPT0WU
TGBC1TKB M1jyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPD[YhKSzVyPUGuO|Ehdk1? MVHTRW5ITVJ?
KURAMOCHI NFnUWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G0bmlEPTB;MT63NkBvVQ>? NYmzU|dOW0GQR1XS
U-266 M3LISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGzd4pWUUN3ME2xMlc3KG6P NWPjbosxW0GQR1XS
LC4-1 NWLu[WNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXJTWM2OD1zLke5JI5O NEPhe3hUSU6JRWK=
NCI-H2126 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1zLkigcm0> NYfkdVBnW0GQR1XS
NCI-H1092 NILhXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwODDuUS=> M3\LV3NCVkeHUh?=
GB-1 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\oNWlEPTB;MT64NUBvVQ>? M2fUdHNCVkeHUh?=
MV-4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPQTWM2OD1zLkiyJI5O NH;LbIhUSU6JRWK=
Becker NFT3eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLiTWM2OD1zLkizJI5O NX;aXpZHW0GQR1XS
MPP-89 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwOEmgcm0> NXfFbmJ5W0GQR1XS
BE-13 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCxTWM2OD1zLkmzJI5O MVHTRW5ITVJ?
697 NVnmNGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HBNWlEPTB;MT65PUBvVQ>? NXna[GI4W0GQR1XS
NKM-1 NF[xTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzjTWM2OD1{IH7N NFnmR2NUSU6JRWK=
NB13 M1H2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjLdINKSzVyPUKgcm0> NF2yNXFUSU6JRWK=
LS-123 M3roVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\FTlNKSzVyPUKuNFIhdk1? MVnTRW5ITVJ?
NB17 MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfyTWM2OD1{LkC0JI5O M{j6[3NCVkeHUh?=
LAN-6 NHzNW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz2TWM2OD1{LkC1JI5O NXO3Sod4W0GQR1XS
EW-24 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwMEigcm0> MnWzV2FPT0WU
NOS-1 M1K0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jkbWlEPTB;Mj6xNUBvVQ>? M4SxfHNCVkeHUh?=
BL-70 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn4TWM2OD1{LkGyJI5O MonCV2FPT0WU
GT3TKB NVv0dWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLlenBpUUN3ME2yMlEzKG6P M3fxVHNCVkeHUh?=
HH MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXHUldnUUN3ME2yMlE{KG6P MkLvV2FPT0WU
KE-37 M4SzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTCTWM2OD1{LkGzJI5O M1z6eXNCVkeHUh?=
MOLT-4 M3fIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjwfZdKSzVyPUKuNVMhdk1? MmLYV2FPT0WU
EKVX M1L6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDh[3pKSzVyPUKuNVQhdk1? M1m0RXNCVkeHUh?=
KGN NHvEdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v2NGlEPTB;Mj6xOUBvVQ>? NHvqSGxUSU6JRWK=
ES4 NFLWXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K1R2lEPTB;Mj6xOkBvVQ>? MkTNV2FPT0WU
SJSA-1 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDKOVJ[UUN3ME2yMlIyKG6P NG\wfXZUSU6JRWK=
KMOE-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37ZcmlEPTB;Mj6yN{BvVQ>? M2KxfHNCVkeHUh?=
NB5 M3;pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjVTWM2OD1{LkK3JI5O MlOyV2FPT0WU
BC-1 NHn4d2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;wTWM2OD1{LkOxJI5O NIPoUYRUSU6JRWK=
NB10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwM{Kgcm0> NFrxSJRUSU6JRWK=
RPMI-8226 M3:1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32zOWlEPTB;Mj6zOUBvVQ>? Mnn5V2FPT0WU
SCC-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\KfGlEPTB;Mj6zO{BvVQ>? MX\TRW5ITVJ?
ARH-77 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPjbohoUUN3ME2yMlM5KG6P MnX5V2FPT0WU
NCI-H748 M4nObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwM{mgcm0> NHK3VHVUSU6JRWK=
KU812 M2L0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTveGFmUUN3ME2yMlQzKG6P NWDQbpNJW0GQR1XS
NCI-H64 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPGeHhKSzVyPUKuOFQhdk1? NW\CToo{W0GQR1XS
NB69 NUnre21JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\KWlRKSzVyPUKuOFYhdk1? NGLRfGhUSU6JRWK=
KNS-81-FD M3;Vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3aTWM2OD1{LkS4JI5O MVnTRW5ITVJ?
LB1047-RCC NYWxdGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjDcmNZUUN3ME2yMlU4KG6P NUfjW|VVW0GQR1XS
EB-3 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP1XY1GUUN3ME2yMlY3KG6P NF\ZV|JUSU6JRWK=
Mo-T M1f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T0UGlEPTB;Mj63OEBvVQ>? MVTTRW5ITVJ?
EW-16 NEHkVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny4TWM2OD1{Lke1JI5O NHHTV5NUSU6JRWK=
CTV-1 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwODDuUS=> NHS5[3FUSU6JRWK=
ETK-1 NIHFPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyxTWM2OD1{Lki0JI5O MVXTRW5ITVJ?
C2BBe1 NVnLNpB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELuSlZKSzVyPUKuPFkhdk1? MYrTRW5ITVJ?
MOLT-16 NV3FSZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDHPFdKSzVyPUKuPFkhdk1? MmHuV2FPT0WU
SW954 NIS1NGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHGN2NKSzVyPUKuPUBvVQ>? NHe3WXZUSU6JRWK=
HT MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwMEKgcm0> MkjYV2FPT0WU
KARPAS-299 M33S[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\YR3dKSzVyPUOuNFYhdk1? M3fOWHNCVkeHUh?=
MONO-MAC-6 M{nKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3nU3FKSzVyPUOuNUBvVQ>? NEfSPYpUSU6JRWK=
CGTH-W-1 NIXWbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjPS3pvUUN3ME2zMlEhdk1? NFnYUllUSU6JRWK=
SK-PN-DW MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S2cWlEPTB;Mz6xOEBvVQ>? M1\kfXNCVkeHUh?=
CW-2 NUHudI9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZUmlEPTB;Mz6yNUBvVQ>? NYOxdm9XW0GQR1XS
SK-N-DZ NXT4T25xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvDOZRjUUN3ME2zMlI3KG6P NH\yNVRUSU6JRWK=
NEC8 M2jMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiwcW9KSzVyPUOuN|Uhdk1? MXHTRW5ITVJ?
LB996-RCC NHjJ[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ztZWlEPTB;Mz60JI5O NWrycoxCW0GQR1XS
DB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfaTmoyUUN3ME2zMlQyKG6P M33rPHNCVkeHUh?=
TE-15 NGficlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7COI9tUUN3ME2zMlQ{KG6P M124fnNCVkeHUh?=
COR-L88 NIPOV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNwNEegcm0> M{nzSHNCVkeHUh?=
LAMA-84 M2PBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXOR4R6UUN3ME2zMlQ6KG6P NFjwRmlUSU6JRWK=
MEG-01 NVPRU2xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnqNnN7UUN3ME2zMlQ6KG6P NVWzVmt[W0GQR1XS
LOXIMVI NFPObpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17ZfWlEPTB;Mz61JI5O NYq1RXlDW0GQR1XS
RPMI-8402 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nVVWlEPTB;Mz61JI5O NE\Bb3pUSU6JRWK=
KARPAS-45 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLETIFKSzVyPUOuOVQhdk1? M{f5eXNCVkeHUh?=
HCC1187 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwNUSgcm0> M2jtXXNCVkeHUh?=
MZ1-PC M1T6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOzXZRKSzVyPUOuOVQhdk1? MYfTRW5ITVJ?
no-11 NF7WfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3sTWM2OD1|LkW1JI5O MV;TRW5ITVJ?
EVSA-T NVXINFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ewdWlEPTB;Mz62JI5O MkjCV2FPT0WU
DJM-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwNkOgcm0> MoD0V2FPT0WU
COLO-684 NIXxWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNTWM2OD1|Lk[2JI5O NILUSIlUSU6JRWK=
NMC-G1 M3LoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojlTWM2OD1|Lk[4JI5O NGj3cFlUSU6JRWK=
LC-1F NX7LfGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnyyTWM2OD1|Lke0JI5O MkHCV2FPT0WU
RL95-2 M124[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3pNGZKSzVyPUOuO|khdk1? NVvSU2tPW0GQR1XS
COLO-320-HSR NHe4UZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;3PWlEPTB;Mz65NkBvVQ>? NV\IbY1GW0GQR1XS
RCC10RGB NECyZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPqTWM2OD1|LkmzJI5O MnLoV2FPT0WU
HD-MY-Z Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTvTWM2OD1|LkmzJI5O MlrkV2FPT0WU
NCI-H2141 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HQSWlEPTB;ND6wOUBvVQ>? M2XPW3NCVkeHUh?=
K-562 NYGzdYhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPYTWM2OD12LkGyJI5O NVrh[29JW0GQR1XS
NCI-H1648 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;4TWM2OD12LkGzJI5O MYTTRW5ITVJ?
OMC-1 NGHiXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLQTWM2OD12LkG4JI5O MUDTRW5ITVJ?
LB647-SCLC M3KxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37KXmlEPTB;ND6yNkBvVQ>? Mo\qV2FPT0WU
TE-12 NWHvTFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewbYo6UUN3ME20MlI2KG6P NInNUJpUSU6JRWK=
NOMO-1 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwM{Ogcm0> MYPTRW5ITVJ?
Raji NH7afYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELKUotKSzVyPUSuOFYhdk1? NH7CdJFUSU6JRWK=
NALM-6 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTyTWM2OD12LkS5JI5O NWPpeZd2W0GQR1XS
HL-60 NETsUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTRwNkegcm0> MmPZV2FPT0WU
IST-SL1 NInaWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwNkigcm0> MUjTRW5ITVJ?
MHH-PREB-1 NXvtTJRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvnTWM2OD12Lki2JI5O NEO2TFVUSU6JRWK=
MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfLVJlJUUN3ME20MlkyKG6P NWK3WVA{W0GQR1XS
JiyoyeP-2003 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\yW2lEPTB;NTDuUS=> M13DRnNCVkeHUh?=
SBC-1 NEnzRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\GNWlEPTB;NT6wNUBvVQ>? NFfse2tUSU6JRWK=
CHP-126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW1[Gw{UUN3ME21MlA3KG6P MYjTRW5ITVJ?
LU-139 NIX6ZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTVwMUOgcm0> M1y5W3NCVkeHUh?=
NCI-SNU-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWxXIt{UUN3ME21MlE4KG6P NVfxXVFDW0GQR1XS
SW962 M2fF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH30XZlKSzVyPUWuNlEhdk1? M4nuc3NCVkeHUh?=
EW-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHKVodKSzVyPUWuN|Ehdk1? NYj5d2pSW0GQR1XS
NCI-H1417 NELHVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwNUGgcm0> MUPTRW5ITVJ?
LU-65 NVvhVpZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVwOESgcm0> NULCS4I6W0GQR1XS
D-502MG MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv5OHBHUUN3ME22MlM4KG6P MV;TRW5ITVJ?
BC-3 M2XQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PkVmlEPTB;Nj62NUBvVQ>? M2H5UXNCVkeHUh?=
GDM-1 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwN{egcm0> NHjzfohUSU6JRWK=
NCI-H2196 NIPqW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq3[4ZvUUN3ME22Mlghdk1? NV3YcXhsW0GQR1XS
NB1 NXjtR5ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK4TWM2OD14Lki4JI5O MYLTRW5ITVJ?
NCI-H345 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zsNWlEPTB;Nz6yJI5O MorrV2FPT0WU
SU-DHL-1 NIThRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3aTWM2OD15LkK0JI5O MkfYV2FPT0WU
JVM-2 NEW5OHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvrUox7UUN3ME23MlI5KG6P M3Lr[nNCVkeHUh?=
LU-134-A NGPob5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKZZR4UUN3ME23MlM6KG6P M4DIcXNCVkeHUh?=
NCI-H1694 M1vtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWzTWM2OD15LkW4JI5O M3vv[nNCVkeHUh?=
NCI-SNU-16 NV3DNoxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQN|RKSzVyPUeuOlUhdk1? Mm[2V2FPT0WU
L-363 NGL6WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfPSGpnUUN3ME23Mlchdk1? MWXTRW5ITVJ?
KG-1 M3P6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTdwOUSgcm0> MnrTV2FPT0WU
MN-60 NHfHUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojLTWM2OD16LkG0JI5O MmD4V2FPT0WU
NB6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRThwNEigcm0> NUDU[2NGW0GQR1XS
MLMA NITZVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ySWlEPTB;OD64OUBvVQ>? NFP3W4ZUSU6JRWK=
ATN-1 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRThwOEmgcm0> MWHTRW5ITVJ?
SK-NEP-1 NH:0b45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLMTWM2OD17LkCxJI5O NGPpSnlUSU6JRWK=
DMS-114 M3XNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPDTWM2OD17Lk[yJI5O M3znRnNCVkeHUh?=
CTB-1 M2fnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCyTYFxUUN3ME25MlY4KG6P M4XxcnNCVkeHUh?=
NCI-H2081 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFyLkC5JI5O NFfDOodUSU6JRWK=
ES5 NUHseY97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD5TWM2OD1zMD6zPEBvVQ>? MVnTRW5ITVJ?
HCC1599 NH\rdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmyTWM2OD1zMT65NUBvVQ>? MmLkV2FPT0WU
NCI-H23 NHjINlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\GOppKSzVyPUGyMlEzKG6P NXTrWHdIW0GQR1XS
NCI-H1581 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF{LkK4JI5O NUjRR4I4W0GQR1XS
JVM-3 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[5RmlEPTB;MUKuPVkhdk1? NILYbFlUSU6JRWK=
NCI-SNU-1 NX3Zfmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6yTWM2OD1zMz6xPUBvVQ>? MXXTRW5ITVJ?
NB7 NUDPO3VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF3LkmyJI5O M3OzW3NCVkeHUh?=
JAR NUHpT|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXhTWM2OD1zNj6xN{BvVQ>? NWSwb3Y4W0GQR1XS
TGW M4m3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF4LkS4JI5O MkTmV2FPT0WU
U-87-MG Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDJfFZ2UUN3ME2xOk44PiCwTR?= NVjkS5Z1W0GQR1XS
NCI-H1436 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF5LkCxJI5O Mme5V2FPT0WU
GOTO MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XkUGlEPTB;MUeuNFYhdk1? NXP5TVFPW0GQR1XS
COLO-800 M3H0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXmbYNKSzVyPUG3MlY1KG6P MY\TRW5ITVJ?
MFM-223 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm5S2NOUUN3ME2xO{46OSCwTR?= MnLwV2FPT0WU
EW-18 NH;4e|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTtfVl6UUN3ME2xO{46PiCwTR?= NUjmN3VnW0GQR1XS
NB14 NF;GUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Jc2lEPTB;MUeuPVghdk1? MV;TRW5ITVJ?
EB2 NV\yeHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF6LkC4JI5O NWLSVFlSW0GQR1XS
EoL-1- MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi0b41UUUN3ME2xPE4{OSCwTR?= M4XlbHNCVkeHUh?=
NCCIT MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPwZYRKSzVyPUG4MlM3KG6P NIj6T5lUSU6JRWK=
DG-75 M1nq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF6Lk[xJI5O M4fKVnNCVkeHUh?=
HCC2218 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF7LkWgcm0> NWr0[3BYW0GQR1XS
TE-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLzTWM2OD1{MD6wPEBvVQ>? M{HMWXNCVkeHUh?=
SF539 M3rvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLZSY1WUUN3ME2yNE43PyCwTR?= NHjLSoRUSU6JRWK=
NCI-H446 NUXZUHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC5W|BWUUN3ME2yNU4yQCCwTR?= MojmV2FPT0WU
IST-MES1 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULl[GxQUUN3ME2yNk44PyCwTR?= MXzTRW5ITVJ?
NCI-H82 NUO2VXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGyOGJKSzVyPUKzMlAzKG6P MV\TRW5ITVJ?
HCC2157 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSzVYNyUUN3ME2yN{4yOyCwTR?= MUTTRW5ITVJ?
EW-12 M2rxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ|LkG3JI5O NX22XpVCW0GQR1XS
SIMA M4fQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPTWM2OD1{Mz6zPEBvVQ>? MV;TRW5ITVJ?
DOHH-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe5Z21zUUN3ME2yN{41PSCwTR?= MVzTRW5ITVJ?
IM-9 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3YTWM2OD1{Mz61OEBvVQ>? MVvTRW5ITVJ?
EC-GI-10 NH7adohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ2LkKzJI5O M1fFeHNCVkeHUh?=
HDLM-2 NHjITWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuxfWVPUUN3ME2yOE42PCCwTR?= NEDTelFUSU6JRWK=
LS-1034 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ3Lke1JI5O M1vyTHNCVkeHUh?=
REH MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ4LkSxJI5O NGfFNm1USU6JRWK=
LU-165 M3fiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S1WmlEPTB;Mk[uO|Ihdk1? NXTpfWo3W0GQR1XS
NH-12 M3uz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjXUoVKSzVyPUK3MlY4KG6P M3K1bXNCVkeHUh?=
WSU-NHL MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPmO5pjUUN3ME2yPE4{QSCwTR?= NEjxW3FUSU6JRWK=
ECC4 NWnSdlY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ6Lke5JI5O M2fmc3NCVkeHUh?=
OCI-AML2 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\XTWM2OD1{OT62PUBvVQ>? MlTxV2FPT0WU
EW-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKz[IFKSzVyPUOwMlU6KG6P M2PqNHNCVkeHUh?=
NCI-H526 M{P5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHXfWdKSzVyPUOyMlU1KG6P MnXQV2FPT0WU
NCI-H719 M4nEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfsTWM2OD1|ND6zNUBvVQ>? NIXrTHZUSU6JRWK=
KARPAS-422 M1XoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN3LkC0JI5O M4\rfHNCVkeHUh?=
SK-MEL-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTN3LkG3JI5O NXHZSHlNW0GQR1XS
ES3 NGW1b5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN3LkG5JI5O Mn:4V2FPT0WU
UACC-812 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rzRmlEPTB;M{WuOFQhdk1? MoXlV2FPT0WU
C8166 M2LDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN3Lkegcm0> MUDTRW5ITVJ?
MDA-MB-134-VI MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7TXIdzUUN3ME2zOU45PyCwTR?= MnzHV2FPT0WU
D-283MED MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX5TWM2OD1|Nz63PUBvVQ>? MlfYV2FPT0WU
SHP-77 NFTZZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\zSYw3UUN3ME2zPE4xOyCwTR?= NF\pSWRUSU6JRWK=
NCI-H2227 M{\zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TRWmlEPTB;NECuOFkhdk1? M{jxWnNCVkeHUh?=
SKM-1 M2GxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HKOmlEPTB;NEKuOlMhdk1? MknBV2FPT0WU
L-428 NHjCXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjFd3pKSzVyPUSzMlg3KG6P Mo[2V2FPT0WU
RPMI-6666 M3PhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M336OmlEPTB;NEWuPFkhdk1? MlTkV2FPT0WU
NCI-H716 NWTtcGtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG4Sm9wUUN3ME20PE45OSCwTR?= MWPTRW5ITVJ?
DMS-79 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\UcWlEPTB;NUCuO|Ehdk1? MYrTRW5ITVJ?
RS4-11 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrIUGZKSzVyPUWwMlg5KG6P NH60O5NUSU6JRWK=
NCI-H720 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml24TWM2OD13MT6xNUBvVQ>? MXvTRW5ITVJ?
MC-CAR MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnjTWNtUUN3ME21NU42OiCwTR?= NXLIcnBuW0GQR1XS
TALL-1 M4HyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK5TmRKSzVyPUWzMlkyKG6P NXfHeIpMW0GQR1XS
NCI-N87 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPvdYFKSzVyPUW0MlE5KG6P M1;H[nNCVkeHUh?=
P30-OHK NEnpUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfLVlV6UUN3ME21OE43OSCwTR?= NH;tXVdUSU6JRWK=
LP-1 NYL1OmFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqOVZ4UUN3ME22NU4zQCCwTR?= NFO1fHBUSU6JRWK=
YT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK5TWM2OD14MT64JI5O M{nsXHNCVkeHUh?=
MRK-nu-1 M1rDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLTd2hKSzVyPU[xMlgzKG6P MVHTRW5ITVJ?
BT-474 NFXSPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZ3IH7N M{C2OXNCVkeHUh?=
NCI-H322M MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZ4LkGxJI5O MUDTRW5ITVJ?
NCI-H128 NH;UUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nhN2lEPTB;N{SuO|chdk1? NEnSRlBUSU6JRWK=
KMS-12-PE MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLjTWM2OD15Nj6yOEBvVQ>? MnvhV2FPT0WU
KP-N-YS NULpdoU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3QRZlKSzVyPUe2Mlc1KG6P MmHWV2FPT0WU
ALL-PO NVq3bmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLoTZp2UUN3ME23O{43PiCwTR?= MmS0V2FPT0WU
EW-13 NX3hO5FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTd5Lke2JI5O NWrTdoFLW0GQR1XS
EW-11 M3LpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[wWXdKSzVyPUe4MlUzKG6P M3rvPXNCVkeHUh?=
SK-N-FI NYXHTllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDTWM2OD16MD6yJI5O NGLPSHFUSU6JRWK=
CAL-148 M4fLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OyVmlEPTB;OEGuPFQhdk1? NH;WTXRUSU6JRWK=
RL MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\RTWM2OD16Nj6wPUBvVQ>? MX\TRW5ITVJ?
AM-38 NGrJPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTh6LkC4JI5O M13VUHNCVkeHUh?=
RH-1 NFXD[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTl7Lki1JI5O M2Hrd3NCVkeHUh?=
NCI-H1770 M2jzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDCWmpxUUN3ME2xNFIvPDlibl2= MlLjV2FPT0WU
SIG-M5 NH2xcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL6WWVKSzVyPUGwOU4xPiCwTR?= MWXTRW5ITVJ?
GR-ST NGX1cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HsU2lEPTB;MUGzMlM1KG6P M2jEWHNCVkeHUh?=
ST486 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFzND6wOkBvVQ>? MlTvV2FPT0WU
NCI-H1650 M4XkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFzNT6yPUBvVQ>? NGX6TW5USU6JRWK=
MHH-CALL-2 NVu3dJV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof3TWM2OD1zMUWuO{BvVQ>? MlnJV2FPT0WU
BV-173 NHe5NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HVdWlEPTB;MUKyMlcyKG6P M2XUSnNCVkeHUh?=
MC116 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33XeGlEPTB;MUS4Mlg2KG6P NGDIbYZUSU6JRWK=
NCI-H524 M1TnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrfpRKSzVyPUG1PU4yKG6P MmHBV2FPT0WU
SCLC-21H MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXJe3AzUUN3ME2xOVkvPDFibl2= Mkj4V2FPT0WU
NCI-H1304 NUTUXpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL2W5ZKSzVyPUG2PU4zOSCwTR?= MmO5V2FPT0WU
NCI-H510A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD2Rm5RUUN3ME2xPFUvOzdibl2= NXfsPHp6W0GQR1XS
NCI-H209 M2HDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC4XVhKSzVyPUG5Ok42OiCwTR?= MnjIV2FPT0WU
KM-H2 M{fKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF7Nz6wOUBvVQ>? NWHBW4FLW0GQR1XS
NCI-H1395 NWXrcGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuxc3FOUUN3ME2yNVAvOTNibl2= MorzV2FPT0WU
NCI-H1155 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDx[296UUN3ME2yN|AvOzJibl2= NFzDWI5USU6JRWK=
COR-L279 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzrTWM2OD1{NUKuNVchdk1? M4T0WnNCVkeHUh?=
NCI-H1299 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrqUGtKSzVyPUK2NU44OSCwTR?= NW\vO5NLW0GQR1XS
EW-22 NVLTR2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD1{NkOuO|Uhdk1? M1W3cXNCVkeHUh?=
SK-MEL-2 M13oZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zMUWlEPTB;MkixMlkhdk1? MnvaV2FPT0WU
KASUMI-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fIVGlEPTB;MkizMlA2KG6P MWrTRW5ITVJ?
NCI-H187 M2HXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfQVmdsUUN3ME2yPFcvODhibl2= MXPTRW5ITVJ?
NCI-H2171 M3Xw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ6OD65NkBvVQ>? M3u2N3NCVkeHUh?=
LNCaP-Clone-FGC MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPnTWM2OD1{OUWuNlYhdk1? NEPj[HpUSU6JRWK=
NCI-H1522 NV;EWZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jzUWlEPTB;M{C3MlA2KG6P NWO5U|hxW0GQR1XS
SCH MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLY[IRVUUN3ME2zNlIvOjJibl2= NVrT[VhqW0GQR1XS
THP-1 NH;1W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jlbGlEPTB;M{KyMlYhdk1? M{Pjd3NCVkeHUh?=
SNU-C1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN4Mj6wPUBvVQ>? MXXTRW5ITVJ?
CA46 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvreJlVUUN3ME2zO|MvPjNibl2= NIn3fJlUSU6JRWK=
NCI-H1963 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN6Nj6xPUBvVQ>? M3WzNHNCVkeHUh?=
DEL MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WxXWlEPTB;M{mxMlI4KG6P MkTJV2FPT0WU
TUR M4T4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq3TWM2OD1|OU[uOlEhdk1? M4X6[XNCVkeHUh?=
NCI-H226 NFXCUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRyMz6yN{BvVQ>? M4DreXNCVkeHUh?=
COLO-668 NYroOIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXewSZZIUUN3ME20NFMvPTdibl2= MlfTV2FPT0WU
CPC-N M{TmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfXelZyUUN3ME20NFMvPzdibl2= Mm\SV2FPT0WU
NCI-H889 NVrEcI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrETWM2OD12NkGuPVIhdk1? M2nDRXNCVkeHUh?=
J-RT3-T3-5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:4fGlEPTB;NUOyMlU4KG6P NYD6[HFEW0GQR1XS
MSTO-211H M4e1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTV5ND6yOkBvVQ>? MoPGV2FPT0WU
SCC-15 M4\ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jD[GlEPTB;Nk[3MlQ4KG6P NFnMT5JUSU6JRWK=
SUP-T1 M4XQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjvZVlKSzVyPU[4Ok4xPCCwTR?= NHfLR5RUSU6JRWK=
DMS-153 M1;yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\OUItKSzVyPUe0Ok45OyCwTR?= NITBVm9USU6JRWK=
MS-1 NWnjZVdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTd3OT60NkBvVQ>? NUfYSpViW0GQR1XS
TC-YIK NYLUSmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfkXHhKSzVyPUe4NU4xOSCwTR?= NV:2NVRLW0GQR1XS
RPMI-8866 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWwTWM2OD1zMEC2MlI5KM7:TR?= MkPzV2FPT0WU
KY821 NX32W2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUThTXM5UUN3ME2xNFM3NjB2IN88US=> NXX4UlhjW0GQR1XS
P31-FUJ MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\CXWJKSzVyPUGxNVIvPzVizszN MlHMV2FPT0WU
COLO-824 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonoTWM2OD1zMk[xMlc5KM7:TR?= M1\3eXNCVkeHUh?=
U-698-M NGHsVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe0fZhKSzVyPUKyOlIvOTVizszN NEfLc2lUSU6JRWK=
TE-441-T M4GzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkRWlEPTB;MkWyNU44KM7:TR?= M4\yNHNCVkeHUh?=
IMR-5 NXXZdlJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7mW40{UUN3ME2zOFA6NjZ{IN88US=> MXzTRW5ITVJ?
NCI-H1838 NW\qRXRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\GTWM2OD12MUi2MlMzKM7:TR?= NVK2em9EW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products3

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID